Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
22 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Maravai LifeSciences Holdings, Inc.’s names, not what it holds today.
Patents granted
22
19 utility, 3 design, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 1 in 2023
Applications published
21
3 of them in 2025
Names they are printed under
4
a subsidiary
By yearGrantedApplications published
'06'09'10'11'12'13'14'17'18'19'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
TriLink BioTechnologies, LLC a subsidiary
US, as the owner printed on each patent
15 publishedGlen Research Corporation a subsidiary
US, as the owner printed on each patent
5 publishedCygnus Technologies, L.L.C. a subsidiary
US, as the owner printed on each patent
0 publishedTriLink BioTechnologies, LLC a subsidiary
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 25, 2025 | 12,258,369 | Compositions and methods for synthesizing 5′-capped RNAs | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Oct 1, 2024 | 12,103,944 | Compositions and methods for synthesizing 5′-capped RNAs | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Jan 23, 2024 | 11,878,991 | Compositions and methods for synthesizing 5′-Capped RNAs | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Feb 14, 2023 | 11,578,095 | Compositions and methods for synthesizing 5'-Capped RNAs | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Aug 16, 2022 | 11,414,453 | Compositions and methods for synthesizing 5′-capped RNAs | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Feb 9, 2021 | 10,913,768 | Compositions and methods for synthesizing 5′-capped RNAs | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Dec 31, 2019 | 10,519,189 | Compositions and methods for synthesizing 5′-Capped RNAs | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Dec 3, 2019 | 10,494,399 | Compositions and methods for synthesizing 5′-Capped RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Apr 25, 2017 | 9,631,227 | Chemically modified ligase cofactors, donors and acceptors | Biotechnology | TriLink BioTechnologies, LLC |
| May 20, 2014 | 8,728,725 | Chemically modified ligase cofactors, donors and acceptors | Biotechnology | TriLink BioTechnologies, LLC |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 25, 2025 | 2025/0388620 | EFFICIENT METHOD FOR MAKING HIGHLY PURIFIED 5’- CAPPED OLIGONUCLEOTIDES | Organic fine chemistry | TriLink BioTechnologies, LLC |
| May 29, 2025 | 2025/0171489 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC |
| Apr 3, 2025 | 2025/0108066 | TRINUCLEOTIDE CAP ANALOGS AND METHODS OF USE THEREOF | Organic fine chemistry | TriLink BioTechnologies, LLC |
| May 16, 2024 | 2024/0158433 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC · patent 12,103,944 granted from it |
| May 2, 2024 | 2024/0140982 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC · patent 12,258,369 granted from it |
| Sep 15, 2022 | 2022/0289786 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC · patent 11,578,095 granted from it |
| Dec 2, 2021 | 2021/0371452 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC · patent 11,414,453 granted from it |
| Aug 26, 2021 | 2021/0261597 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC · patent 11,878,991 granted from it |
| Sep 5, 2019 | 2019/0270766 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC · patent 10,494,399 granted from it |
| May 16, 2019 | 2019/0144490 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | Pharmaceuticals | TriLink BioTechnologies, LLC · patent 10,519,189 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Organic fine chemistry 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.